- Home
- ASTH vs NVCR Comparison
ASTH vs NVCR Comparison
Compare ASTH & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASTH | NVCR |
|---|---|---|
| Founded | 1994 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.5B |
| IPO Year | 2015 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ASTH | NVCR |
|---|---|---|
| Price | $24.26 | $12.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $35.33 | $28.08 |
| AVG Volume (30 Days) | 500.6K | ★ 2.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ 0.46 | N/A |
| Revenue | $519,907,752.00 | ★ $655,353,000.00 |
| Revenue This Year | $26.88 | $7.72 |
| Revenue Next Year | $10.78 | $6.74 |
| P/E Ratio | $50.54 | ★ N/A |
| Revenue Growth | ★ 45.90 | 8.28 |
| 52 Week Low | $18.08 | $9.82 |
| 52 Week High | $34.80 | $20.05 |
Technical Indicators
Market Signals| Indicator | ASTH | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 54.88 | 46.12 |
| Support Level | $20.98 | $10.86 |
| Resistance Level | $28.02 | $14.13 |
| Average True Range (ATR) | 1.47 | 0.99 |
| MACD | 0.28 | -0.10 |
| Stochastic Oscillator | 67.40 | 24.61 |
Price Performance
Historical ComparisonAbout ASTH Astrana Health Inc.
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.